Needham analyst Mike Matson downgraded CONMED (NYSE: CNMD) from Buy to Hold.The analyst comments "CNMD's long-term growth rate has decreased ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE